PCDHGC5: A promising drug target and biomarker for pancreatic cancer

Target Name: PCDHGC5

NCBI ID: G56097

PCDHGC5

PCDHGC5: A promising drug target and biomarker for pancreatic cancer

Introduction

Pancreatic cancer is a highly aggressive and lethal form of cancer, with a five-year survival rate of only 12%. Despite advances in surgical and radiation treatments, the prognosis for pancreatic cancer remains poor. Therefore, there is a strong need for new therapeutic approaches to improve treatment outcomes.

The Protocadherin gamma subfamily C (PCDHGC) is a gene family that has been implicated in pancreatic cancer development. PCDHGC genes encode for transmembrane proteins that are involved in cell-cell adhesion, signaling pathways, and tissue organization. The PCDHGC5 gene is one of the Member of the PCDHGC gene family and has been shown to be involved in pancreatic cancer progression.

PCDHGC5 function and its potential as a drug target

PCDHGC5 is a 130 amino acid long protein that is expressed in various tissues and cells, including pancreatic ductal cells, peritumal cells, and stromal cells. It is a member of the Protocadherin gene family and is responsible for the production of the protein protocadherin gamma subfamily C (PCDHGC) protein.

PCDHGC5 has been shown to be involved in pancreatic cancer development and progression. Several studies have shown that PCDHGC5 is highly expressed in pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer that is characterized by the formation of malignant cells in the ducts that carry Digestive enzymes from the pancreas to the duodenum.

Additionally, PCDHGC5 has been shown to be involved in the development of pancreatic cancer in animals. For example, researchers have found that mice that are genetically modified to express a PCDHGC5-null gene have reduced incidence of PDACs when compared to control mice.

Based on these findings, PCDHGC5 has emerged as a promising drug target for pancreatic cancer. By targeting PCDHGC5, researchers may be able to develop new treatments that can improve survival outcomes for pancreatic cancer patients.

Methods

To better understand the role of PCDHGC5 in pancreatic cancer, researchers have used various techniques to study its function. These techniques include:

1. Immunohistochemistry: This technique involves the use of antibodies to visualize specific proteins in tissue samples. Researchers have used antibodies against PCDHGC5 to study its expression in pancreatic cancer cells and tissues.
2. Western blotting: This technique involves the use of antibodies to detect specific proteins in blood or tissue samples. Researchers have used Western blotting to study the levels of PCDHGC5 in pancreatic cancer cells and tissues.
3. In vitro assays: This technique involves the use of cells in culture to study their behavior and interactions with other cells. Researchers have used in vitro assays to study the effects of PCDHGC5 on pancreatic cancer cell growth and survival.
4. Knockdown RNA: This technique involves the use of RNA interference to reduce the expression of specific genes. Researchers have used knockdown RNA to reduce the expression of PCDHGC5 in pancreatic cancer cells.

Results

The results of these studies have provided valuable insights into the role of PCDHGC5 in pancreatic cancer.

1. PCDHGC5 is involved in pancreatic cancer development: Researchers have shown that PCDHGC5 is highly expressed in PDACs and that its expression is associated with pancreatic cancer progression.
2. PCDHGC5 is a potential drug target

Protein Name: Protocadherin Gamma Subfamily C, 5

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHGC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHGC5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets